OpenAI-Backed Startup Red Queen Bio Ramps Up AI-Designed Antibody Defense Pipeline

Red Queen Bio, an AI biosecurity startup backed by OpenAI and other mission-focused investors, is rapidly advancing its pipeline to design and manufacture antibodies as a preventive shield against potential pathogens—including those that could be engineered using artificial intelligence. The company, founded by physicist and serial entrepreneur Hannu Rajaniemi and spun out from mRNA therapeutics firm HelixNano, closed a $15 million seed round led by OpenAI in late 2025, with backing from Cerberus Ventures, Fifty Years, and Halcyon Futures—all investors focused on dual-use safety and biodefense.